Spatial Genomics, Transcriptomics and Proteomics Solutions Market - Distribution by Type of Solution (Instruments, Consumables and Services), Type of Sample (DNA, RNA and Proteins), End Users (Pharmaceutical and Biotechnology Companies, and Academic and Research institutes), Research Areas (Oncology, Immunology, Neurology, Infectious and Others), and Key Geographical Regions (North America, Europe, and Asia-Pacific and the Rest of the World): Industry Trends and Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2022

  • Pages
    213

  • View Count
    290

Example Insights

Spatial-Genomics-Transcriptomics-and-Proteomics-Context-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-business-model-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Profiling-Solutions-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Developer-Landscape-thumb
Spatial-Genomics-Transcriptomics-and-Proteomics-Competitiveness-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Collaborations-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Publication-Analysis-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Patent-Analysis-thumb
Spatial-Genomics-Transcriptomics-and-Proteomics-Imaging-Instruments-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Parameters-Controlled-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-Solutions-Market-thumb Spatial-Genomics-Transcriptomics-and-Proteomics-End-Users-thumb

Overview

Since the discovery of the first human genetic map in 1987, the field of omics-based analysis has evolved significantly. Researchers have focused their efforts from decoding the primary sequence of genes to analyzing the location and interaction of cell types, and biomarkers (primarily, DNA, RNA and proteins), through a process known as spatial phenotyping. The traditional molecular profiling analytical techniques, such as microarrays quantitative polymerase chain reaction (qPCR), flow cytometry, mass spectrometry, immunohistochemistry and enzyme linked immunosorbent (ELISA) assay, though widely adopted, are known to dissociate the tissue samples, thereby causing loss of critical spatial multi-omics information across the genome, transcriptome, and proteome. This unmet need in the life sciences research market has prompted innovators to amalgamate cell imaging and molecular profiling techniques to enable visualization, as well as high-throughput quantification of the cells and biomarkers within the tissue samples. These solutions (that include platforms, along with affiliated reagents and software applications) enable the researchers to further advance and scale their research, by offering a better understanding of the disease morphology, discover novel / digital biomarkers and develop precision therapies. Additionally, these spatial phenotyping platforms can be seamlessly integrated with the current next generation sequencing NGS-workflows. Therefore, the adoption of these novel devices to scale research from discovery to translational and clinical phases, is on the rise. In fact, according to a recent survey, approximately 44% of respondents expressed their intent to purchase a spatial profiling platform. In the same year, a research study, published in JAMA Oncology, emphasized the superiority of spatial phenotyping methods for the biomarker analysis in patients suffering from immuno-oncological diseases. Further, Nature Methods dubbed Spatial Transcriptomics as “Method of the Year” for 2020.

In order to capitalize the growing opportunity within this niche market, the developers of spatial-omics solutions are engaged in efforts to improve the penetration of their proprietary technologies, within the diverse client base, including academic research centers, research institutes and biopharma companies. As a result, they are engaged in incorporating advanced features to their devices, including machine learning-based image analysis, automated sample processing, high-multiplexing, and biomarker-specific gene panels (including those associated with SARS-CoV-2). At the same time, the cost of running these complex tests has dramatically decreased in recent years; the spatial analysis of high-plex stained panels now costs USD 1,000 per slide, which is similar to the cost of whole genome sequencing by NGS. Further, these instruments are designed to be capable of processing formalin-fixed paraffin embedded (FFPE) tissue sample. This feature is important because nearly 80% of the translational research studies, that use tissue samples, are dependent on the aforementioned sample type. Few players have also introduced customized access programs for biopharmaceutical players, enabling them to leverage spatial omics technologies, for the purpose of guiding their drug development programs. Driven by the growing adoption and continuous innovation of spatial biology solutions, we are led to believe that the opportunity for spatial profiling solution providers is likely to witness a sustained growth over the coming years.

Scope of the Report

The “Spatial Genomics, Transcriptomics and Proteomics Solutions Market, 2022-2035” report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the spatial omics solutions market. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of the spatial genomics, transcriptomics and proteomics solutions, highlighting the contributions of industry players, along with information on their year of establishment, company size, company ownership, location of headquarters, commercial availability, type of solution(s) offered, type of sample(s) analyzed (fresh frozen, FFPE, tissue microarrays and cellular), compatible sample source (human and murine), supported labware for sampling (test tubes, slides and well plates), type of molecule(s) analyzed (RNA, DNA and protein), detection method(s) used (fluorescence, brightfield and mass spectrometry), maximum plex level, quantification capability of analyte, research area(s) and  application area(s).
  • A detailed competitiveness analysis of products (devices / platforms / assays) based on parameters, such as supplier power (based on the experience of the developer and company size) and product specifications (type of sample analyzed, supported labware for sampling, type of molecule analyzed, detection method used, maximum plex level, quantification capability and compatible sample source).
  • Elaborate profiles of key players offering spatial omics solutions. Each profile includes a brief overview of the company, its financial information (if available), information on its spatial biology solutions portfolio, recent developments, and an informed outlook.
  • An analysis of the partnerships that have been established in this domain during 2017-2022, featuring a detailed set of analyses based on various parameters, such as type of partnership, year of partnership, therapeutic areas involved, geographical location of the companies involved and the most active players.
  • An in-depth analysis of the patents that have been filed / granted for spatial omics solutions since 2003, based on important parameters such as, type of patent, patent application year, publication year, granted patents, year-wise trend of filed patent applications, number of granted patents and patent applications, geography, patent age, type of applicant, CPC symbols, leading industry and non-industry players (on the basis of number of patents), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis. 
  • A detailed review of more than 600 peer-reviewed, scientific articles related to research on spatial omics solutions, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on the top journals, top publishers and top copyright holders (in terms of number of articles published)
  • A detailed review of the overall landscape of the live cell instruments market, highlighting the contributions of industry players, along with information on their year of establishment, company size, geographical location of headquarters, ownership, commercial availability, microscope configuration, instrument weight, availability of integrated incubator, environmental parameters controlled, availability of multi-user mode, supported labware, Z-stack imaging capability, autofocusing capability, mode of imaging, number of fluorescent channels and magnification.

One of the key objectives of the report was to estimate the existing market size and the potential future growth opportunity associated with spatial omics solutions providers in the mid to long term. We have developed informed estimates on the evolution of the market for the period 2022-2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across different segments; type of solution (instruments, consumables and services), type of sample analyzed (DNA, RNA and protein), end users (academic research institutes and pharmaceutical companies), research areas (oncology, immunology, neurology, infectious and others), and key geographical locations (North America, Europe and Asia- Pacific and the Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry’s growth. 

The opinions and insights presented in the report were influenced by discussions held with several stakeholders engaged in this domain. The report features detailed transcripts of discussions held with the following individuals:

  • Priyam Shah (Senior Director, Akoya Biosciences)
  • Sean Bendall (Co-founder, Ionpath)
  • Brad Nelson (Senior Vice President of Marketing, Ionpath)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Which are the key geographies where spatial omics solutions providers are located?
  • Which analytical techniques are leveraged by the solution providers engaged in spatial omics solutions market?
  • Who are the leading developers involved in the development of spatial omics solutions?
  • For which research applications are spatial analysis solutions most widely used?
  • Which partnership models are commonly adopted by stakeholders offering spatial profiling solutions?
  • What is the evolving trend of publications focused on spatial analysis-based technologies?
  • Who are the key investors in spatial omics solutions market? 
  • Which companies are actively filing patents to drive innovation in spatial omics solutions market?
  • How is the current and future opportunity likely to be distributed across key market segment?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state and likely evolution of the spatial omics solutions market, in the mid to long term.

Chapter 3 provides a general introduction to spatial omics solutions, the need and evolution of these solutions. In addition, the chapter includes information on the various features of spatial analysis solutions and the techniques used in spatial biology analysis, particularly focusing on fluorescence microscopy, brightfield microscopy, and mass spectroscopy. The chapter also discusses the different components and working procedure of spatial analysis instruments, and the potential of spatial profiling solutions across oncological and non-oncological disease areas. Further, the chapter provides an overview of the existing challenges and future anticipated trends, within this domain.

Chapter 4 provides an overview of the current market landscape of the spatial genomics, transcriptomics and proteomics solutions, including information on 40+ players offering these solutions, along with information on their year of establishment, company size (large, mid–sized and small), ownership (private, public), geographical location of headquarters (North America, Europe and Asia-Pacific), commercial availability (commercialized and under developed), type of solution(s) offered (product and / or service), type of sample(s) analyzed (fresh frozen, FFPE, tissue microarrays and cellular), compatible sample source (human, murine), supported labware for sampling (test tubes, slides and well plates), type of molecule(s) analyzed (RNA, DNA and protein), detection method(s) used (fluorescence, brightfield and mass spectrometry), maximum plex level, quantification capability of analyte, research area(s) and  application area(s).

Chapter 5 provides an insightful competitiveness analysis of spatial omics technologies, based on parameters, such as supplier strength (in terms of years of experience of developer and company size), and portfolio diversity (type of sample analyzed, supported labware for sampling, type of molecule analyzed, detection method used, maximum plex level, quantification capability and compatible sample source).

Chapter 6 includes detailed profiles of prominent solution providers in this domain. Each company profile includes a brief overview of the company, its financial information (if available), information on its spatial biology solutions portfolio, recent developments, and an informed outlook.

Chapter 7 presents an analysis of the partnerships and collaborations established for spatial genomics, transcriptomics and proteomics solutions during 2017-2022, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, therapeutic areas involved, geographical location of the companies involved and the most active players.

Chapter 8 presents in-depth analysis of the patents that have been filed / granted for spatial profiling solutions since 2003. It highlights trends across the key parameters associated with the patents, including type of patent, patent application year, publication year, number of granted patents and patent applications, geography, patent age, type of applicant, CPC symbols, leading industry and non-industry players (on the basis of number of patents), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis. 

Chapter 9 presents a detailed review 600+ peer-reviewed, scientific articles related to research on spatial omics solutions, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on the top journals, top publishers, and top copyright holders (in terms of number of articles published).

Chapter 10 presents a detailed review of the overall landscape of the live cell instruments market, highlighting the contributions of industry players, along with information on their year of establishment, company size (large, mid-sized and small), geographical location of headquarters(North America, Europe, Asia-Pacific), ownership (private, public),  commercial availability (commercialized, under developed), microscope configuration (inverted, upright), instrument weight, availability of integrated incubator, environmental parameters controlled (temperature, humidity, gas control, pH and osmolarity), availability of multi-user mode, supported labware (flasks, dishes, slides, plates, well plates, microfluidic chips and hemocytometers), Z-stack imaging capability, autofocusing capability, mode of imaging (fluorescence, brightfield, phase- contrast, confocal, differential interference contrast (DIC), Hoffman modulation contrast (HMC) and colorimetric, number of fluorescent channels and magnification.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of the spatial genomics, transcriptomics, and proteomics solutions market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across different segments on the basis of [A] type of solution (instruments, consumables and services), [B] type of sample (DNA, RNA and protein), [C] end users (pharmaceutical and biotechnology companies, and academic and research institutes), [D] research areas (oncology, immunology, neurology, infectious and others), [E] key geographical locations (North America, Europe and Asia-Pacific and the Rest of the World).

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Priyam Shah, (Senior Director, Akoya Biosciences), Sean Bendall (Co-founder, Ionpath) and Brad Nelson (Senior Vice President of Marketing, Ionpath)

Chapter 13 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the spatial analysis market.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Spatial Omics Solutions
3.2.1. Evolution of Spatial Omics Solutions
3.2.2. Need for Spatial Omics Solutions
3.2.3. Features of Spatial Omics Solutions
3.2.4. Techniques Used in Spatial Omics Analysis
3.2.4.1. Fluorescence Microscopy
3.2.4.2. Brightfield Microscopy
3.2.4.3. Mass Spectrometry

3.3. Spatial Omics Instruments
3.3.1. Instrument Components
3.3.2. Instrument Workflow

3.4. Application Areas
3.4.1. Role of Spatial Omics Solutions in Oncological Indications
3.4.2. Role of Spatial Omics Solutions in Non-oncological Indications

3.5. Future Perspectives

4. SPATIAL OMICS SOLUTIONS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Spatial Omics Solutions
4.2.1. Analysis by Commercial Availability
4.2.2. Analysis by Type of Solution Offered
4.2.3. Analysis by Type of Sample Analyzed
4.2.4. Analysis by Compatible Sample Source
4.2.5. Analysis by Supporting Labware for Sampling
4.2.6. Analysis by Type of Molecule Analyzed
4.2.7. Analysis by Detection Method Used
4.2.8. Analysis by Maximum Plex Level
4.2.9. Analysis by Quantification Capability of Analyte
4.2.10. Analysis by Research Area
4.2.11. Analysis by Application Area
4.3. Spatial Omics Solutions: List of Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Ownership

5. SPATIAL OMICS SOLUTION PROVIDERS: PRODUCT COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions / Key Parameters
5.3 Methodology
5.4 Competitiveness Analysis: Spatial Omics Solution Providers
5.4.1 Peer Group I: Small Companies
5.4.2. Peer Group II: Mid-sized Companies
5.4.3. Peer Group III: Large Companies

6. SPATIAL OMICS SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Key Players in North America
6.2.1. 10X Genomics
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook

6.2.2. Akoya Biosciences
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Bruker
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook

6.2.4. Canopy Biosciences
6.2.4.1. Company Overview
6.2.4.2 Financial Information
6.2.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook

6.2.5. NanoString Technologies
6.2.5.1. Company Overview
6.2.5.2. Product Portfolio
6.2.5.3. Recent Developments and Future Outlook

6.2.6. Vizgen
6.2.6.1. Company Overview
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook

6.3. Key Players in Europe
6.3.1. Lunaphore Technologies
6.3.1.1. Company Overview
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Molecular Machines & Industries (MMI)
6.3.2.1. Company Overview
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook

6.3.3. Resolve Biosciences
6.3.3.1. Company Overview
6.3.3.2. Product Portfolio
6.3.3.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partner
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Analysis by Type of Partnership and Type of Partner
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Regional Analysis
7.3.9. Intercontinental and Intracontinental Agreements

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2 Methodology and Key Parameters
8.3 Spatial Omics Solutions: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Patent Application Year
8.3.3. Analysis by Publication Year
8.3.4. Analysis by Granted Patents
8.3.5. Year-wise Trend of Filed Patent Applications
8.3.6. Analysis by Number of Granted Patents and Patent Applications
8.3.7. Analysis by Geography
8.3.8. Analysis by Patent Age
8.3.9. Analysis by Type of Applicant
8.3.10. Analysis by CPC Symbols
8.3.11. Leading Players: Analysis by Number of Patents
8.3.12. Top Inventors: Analysis by Number of Patents
8.3.13. Patent Benchmarking Analysis
8.3.14. Patent Valuation Analysis

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2 Methodology and Key Parameters
9.3. Spatial Omics Solutions: Publication Analysis
9.3.1. Analysis by Quarterly Trend of Publications
9.3.2. Analysis by Type of Publication
9.3.3. Popular Journals: Analysis by Number of Patents
9.3.4. Popular Publishers: Analysis by Number of Patents
9.3.5. Popular Copyright Holders: Analysis by Number of Patents
9.3.6. Popular Keywords: Analysis by Number of Patents

10. CASE STUDY ON POTENTIAL CLIENTS OF SPATIAL OMICS SOLUTION PROVIDERS
10.1. Chapter Overview
10.2. Live Cell Instrument Providers: List of Players
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Location of Headquarters
10.2.4. Analysis by Company Ownership
10.3 List of Live Cell Instruments
10.3.1. Analysis by Commercial Availability
10.3.2. Analysis by Microscope Configuration
10.3.3. Analysis by Instrument Weight
10.3.4. Analysis by Availability of Integrated Incubator
10.3.5. Analysis by Environmental Parameters Controlled
10.3.6. Analysis by Availability of Multi-user Mode
10.3.7. Analysis by Supported Labware / Cell Culture Vessel
10.3.8. Analysis by Z-stack Imaging Capability
10.3.9. Analysis by Availability of Autofocus / Semi-Autofocus Mode
10.3.10. Analysis by Mode of Imaging
10.3.11. Analysis by Number of Fluorescence Channels
10.3.12. Analysis by Range of Objectives Available

11. SPATIAL OMICS SOLUTION PROVIDERS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1 Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Global Spatial Omics Solutions Market, 2022-2035
11.3.1. Spatial Omics Solutions Market: Distribution by Type of Solution, 2022-2035
11.3.2. Spatial Omics Solutions Market: Distribution by Type of Sample Analyzed, 2022-2035
11.3.3. Spatial Omics Solutions Market: Distribution by Therapeutic Area, 2022-2035
11.3.4. Spatial Omics Solutions Market: Distribution by End Users, 2022-2035
11.3.5. Spatial Omics Solutions Market: Distribution by Region, 2022-2035

11.4. Spatial Omics Solutions Market in North America, 2022-2035
11.4.1. Spatial Omics Solutions Market in North America: Distribution by Type of Solution, 2022-2035
11.4.2. Spatial Omics Solutions Market in North America: Distribution by Type of Sample Analyzed, 2022-2035
11.4.3. Spatial Omics Solutions Market in North America: Distribution by Therapeutic Area, 2022-2035
11.4.4. Spatial Omics Solutions Market in North America: Distribution by End Users, 2022-2035

11.5. Spatial Omics Solutions Market in Europe, 2022-2035
11.5.1. Spatial Omics Solutions Market in Europe: Distribution by Type of Solution, 2022-2035
11.5.2. Spatial Omics Solutions Market in Europe: Distribution by Type of Sample Analyzed, 2022-2035
11.5.3. Spatial Omics Solutions Market in Europe: Distribution by Therapeutic Area, 2022-2035
11.5.4. Spatial Omics Solutions Market in Europe: Distribution by End Users, 2022-2035

11.6. Spatial Omics Solutions Market in Asia-Pacific and Rest of the World, 2022-2035
11.6.1. Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Type of Solution, 2022-2035
11.6.2. Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Type of Sample Analyzed, 2022-2035
11.6.3. Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035
11.6.4. Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by End Users, 2022-2035

12. EXECUTIVE INSIGHTS

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Segments of Spatial Omics
Figure 3.2 Historical Timeline: Launch of Spatial Omics Solutions
Figure 3.3 Features of Spatial Omics Solutions
Figure 3.4 Preparation of Fresh Frozen Tissue Sample
Figure 3.5 Preparation of FFPE Tissue Sample
Figure 3.6 Working of a Spatial Analysis Instrument
Figure 4.1 Spatial Omics Solutions: Distribution by Commercial Availability
Figure 4.2 Spatial Omics Solutions: Distribution by Type of Solution Offered
Figure 4.3 Spatial Omics Solutions: Distribution by Type of Sample Analyzed
Figure 4.4 Spatial Omics Solutions: Distribution by Compatible Sample Source
Figure 4.5 Spatial Omics Solutions: Distribution by Supporting Labware for Sampling
Figure 4.6 Spatial Omics Solutions: Distribution by Type of Molecule Analyzed
Figure 4.7 Spatial Omics Solutions: Distribution by Detection Method Used
Figure 4.8 Spatial Omics Solutions: Distribution by Maximum Plex Level
Figure 4.9 Spatial Omics Solutions: Distribution by Quantification Capability of Analyte
Figure 4.10 Spatial Omics Solutions: Distribution by Research Area
Figure 4.11 Spatial Omics Solutions: Distribution by Application Area
Figure 4.12 Spatial Omics Solution Providers: Distribution by Year of Establishment
Figure 4.13 Spatial Omics Solution Providers: Distribution by Company Size
Figure 4.14 Spatial Omics Solution Providers: Distribution by Location Of Headquarters
Figure 4.15 Spatial Omics Solution Providers: Distribution by Company Ownership
Figure 4.16 World Map Representation: Distribution by Geography
Figure 4.17 Grid Representation: Distribution by Company Size, Location of Headquarters, and Type of Solution Offered
Figure 4.18 Grid Representation: Distribution by Company Size, Location of Headquarters, and Detection Method Used
Figure 5.1 Product Competitiveness Analysis: Spatial Omics Solutions Offered by Small Companies (Peer Group 1)
Figure 5.2 Product Competitiveness Analysis: Spatial Omics Solutions Offered by Mid-sized Companies (Peer Group 2)
Figure 5.3 Product Competitiveness Analysis: Spatial Omics Solutions Offered by Large Companies (Peer Group 3)
Figure 6.1 10x Genomics: Annual Revenues, FY 2017-2021 (USD Billion)
Figure 6.2 Akoya Biosciences: Annual Revenues, FY 2019-2021 (USD Million)
Figure 6.3 Bruker: Annual Revenues, FY 2017-2021 (USD Million)
Figure 6.4 NanoString Technologies: Annual Revenues, FY 2017-2021 (USD Billion)
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Regional Distribution
Figure 7.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Distribution by Patent Application Year
Figure 8.3 Patent Analysis: Distribution by Publication Year
Figure 8.4 Patent Analysis: Distribution by Granted Patents
Figure 8.5 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications
Figure 8.6 Patent Analysis: Distribution by Number of Granted Patents and Patent Applications
Figure 8.7 Patent Analysis: Distribution by Geography
Figure 8.8 Patent Analysis: Distribution by Patent Age
Figure 8.9 Patent Analysis: Distribution by Type of Applicant
Figure 8.10 Patent Analysis: Distribution by CPC Symbols
Figure 8.11 Leading Players: Distribution by Number of Patents
Figure 8.12 Top Inventors: Distribution by Number of Patents
Figure 8.13 Patent Analysis: Patent Benchmarking Analysis
Figure 8.14 Patent Analysis: Patent Valuation Analysis
Figure 9.1 Publication Analysis: Distribution by Quarterly Trend of publications
Figure 9.2 Publication Analysis: Distribution by Type of Publication
Figure 9.3 Popular Journals: Distribution by Number of Patents
Figure 9.4 Popular Publishers: Distribution by Number of Patents
Figure 9.5 Popular Copyright Holders: Distribution by Number of Patents
Figure 9.6 Patent Analysis: Emerging Focus Areas
Figure 10.1 Live Cell Instrument Providers: Distribution by Year of Establishment
Figure 10.2 Live Cell Instrument Providers: Distribution by Company Size
Figure 10.3 Live Cell Instrument Providers: Distribution by Location of Headquarters
Figure 10.4 Live Cell Instrument Providers: Distribution by Company Ownership
Figure 10.5 Live Cell Instruments: Distribution by Commercial Availability
Figure 10.6 Live Cell Instruments: Distribution by Microscope Configuration
Figure 10.7 Live Cell Instruments: Distribution by Instrument Weight
Figure 10.8 Live Cell Instruments: Distribution by Availability of Integrated Incubator
Figure 10.9 Live Cell Instruments: Distribution by Environmental Parameters Controlled
Figure 10.10 Live Cell Instruments: Distribution by Availability of Multi-user Mode
Figure 10.11 Live Cell Instruments: Distribution by Supported Labware / Cell Culture Vessel
Figure 10.12 Live Cell Instruments: Distribution by Z-stack Imaging Capability
Figure 10.13 Live Cell Instruments: Distribution by Availability of Autofocus / Semi-Autofocus Mode
Figure 10.14 Live Cell Instruments: Distribution by Mode of Imaging
Figure 10.15 Live Cell Instruments: Distribution by Number of Fluorescence Channels
Figure 10.16 Live Cell Instruments: Distribution by Range of Objectives Available
Figure 10.17 World Map Representation: Distribution by Geography
Figure 11.1 Global Spatial Omics Solutions Market, 2022-2035 (USD Million)
Figure 11.2 Spatial Omics Solutions Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 11.3 Global Spatial Omics Solutions Market: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Figure 11.4 Global Spatial Omics Solutions Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 11.5 Global Spatial Omics Solutions Market: Distribution by End Users, 2022-2035 (USD Million)
Figure 11.6 Global Spatial Omics Solutions Market: Distribution by Region, 2022-2035 (USD Million)
Figure 11.7 Spatial Omics Solutions Market in North America, 2022-2035 (USD Million)
Figure 11.8 Spatial Omics Solutions Market in North America: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 11.9 Spatial Omics Solutions Market in North America: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Figure 11.10 Spatial Omics Solutions Market in North America: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 11.11 Spatial Omics Solutions Market in North America: Distribution by End Users, 2022-2035 (USD Million)
Figure 11.12 Spatial Omics Solutions Market in Europe, 2022-2035 (USD Million)
Figure 11.13 Spatial Omics Solutions Market in Europe: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 11.14 Spatial Omics Solutions Market in Europe: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Figure 11.15 Spatial Omics Solutions Market in Europe: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 11.16 Spatial Omics Solutions Market in Europe: Distribution by End Users, 2022-2035 (USD Million)
Figure 11.17 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 11.18 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 11.19 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Figure 11.20 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 11.21 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by End Users, 2022-2035 (USD Million)
Figure 12.1 Concluding Remarks: Overall Market Landscape of Spatial Omics Solution Providers
Figure 12.2 Concluding Remarks: Overall Market Landscape of Spatial Omics Solutions
Figure 12.3 Concluding Remarks: Product Competitiveness Analysis
Figure 12.4 Concluding Remarks: Partnerships and Collaborations
Figure 12.5 Concluding Remarks: Patent Analysis
Figure 12.6 Concluding Remarks: Publication Analysis
Figure 12.7 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Contrasting Characteristics: Fluorescence Microscopy and Brightfield Microscopy
Table 4.1 Spatial Omics Solutions: List of Solutions
Table 4.2 Spatial Omics Solutions: List of Solution Developers
Table 6.1 Spatial Omics Solutions: List of Companies Profiled
Table 6.2 10x Genomics: Company Snapshot
Table 6.3 10x Genomics: Product Portfolio
Table 6.4 10x Genomics: Recent Developments and Future Outlook
Table 6.5 Akoya Biosciences: Company Snapshot
Table 6.6 Akoya Biosciences: Product Portfolio
Table 6.7 Akoya Biosciences: Recent Developments and Future Outlook
Table 6.8 Bruker: Company Snapshot
Table 6.9 Bruker: Product Portfolio
Table 6.10 Bruker: Recent Developments and Future Outlook
Table 6.11 Canopy Biosciences: Company Snapshot
Table 6.12 Canopy Biosciences: Product Portfolio
Table 6.13 Canopy Biosciences: Recent Developments and Future Outlook
Table 6.14 Lunaphore Technologies: Company Snapshot
Table 6.15 Lunaphore Technologies: Product Portfolio
Table 6.16 Lunaphore Technologies: Recent Developments and Future Outlook
Table 6.17 Molecular Machines & Industries (MMI): Company Snapshot
Table 6.18 Molecular Machines & Industries (MMI): Product Portfolio
Table 6.19 Molecular Machines & Industries (MMI): Recent Developments and Future Outlook
Table 6.20 NanoString Technologies: Company Snapshot
Table 6.21 NanoString Technologies: Product Portfolio
Table 6.22 NanoString Technologies: Recent Developments and Future Outlook
Table 6.23 Resolve Biosciences: Company Snapshot
Table 6.24 Resolve Biosciences: Product Portfolio
Table 6.25 Resolve Biosciences: Recent Developments and Future Outlook
Table 6.26 Vizgen: Company Snapshot
Table 6.27 Vizgen: Product Portfolio
Table 6.28 Vizgen: Recent Developments and Future Outlook
Table 7.1 Spatial Omics Solutions: List of Partnerships and Collaborations, 2016-2022 (till April)
Table 8.1 Patent Analysis: Prominent CPC Symbols
Table 8.2 Patent Analysis: Most Popular CPC Symbols
Table 8.3 Patent Analysis: List of Top CPC Symbols
Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 8.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 9.1 Spatial Omics Solutions: List of Publications, 2001-2022 (till March)
Table 10.1 Live Cell Imaging: List of Instrument Providers
Table 10.2 Live Cell Imaging: List of Instruments
Table 14.1 Spatial Omics Solutions: Distribution by Commercial Availability
Table 14.2 Spatial Omics Solutions: Distribution by Type of Solution Offered
Table 14.3 Spatial Omics Solutions: Distribution by Type of Sample Analyzed
Table 14.4 Spatial Omics Solutions: Distribution by Compatible Sample Source
Table 14.5 Spatial Omics Solutions: Distribution by Supporting Labware for Sampling
Table 14.6 Spatial Omics Solutions: Distribution by Type of Molecule Analyzed
Table 14.7 Spatial Omics Solutions: Distribution by Detection Method Used
Table 14.8 Spatial Omics Solutions: Distribution by Maximum Plex Level
Table 14.9 Spatial Omics Solutions: Distribution by Quantification Capability of Analyte
Table 14.10 Spatial Omics Solutions: Distribution by Research Area
Table 14.11 Spatial Omics Solutions: Distribution by Application Area
Table 14.12 Spatial Omics Solutions: Distribution by Year of Establishment
Table 14.13 Spatial Omics Solutions: Distribution by Company Size
Table 14.14 Spatial Omics Solutions: Distribution by Location of Headquarters
Table 14.15 Spatial Omics Solutions: Distribution by Company Ownership
Table 14.16 World Map Representation: Distribution by Geography
Table 14.17 Product Competitiveness Analysis: Distribution of Spatial Omics Solutions Offered by Small Companies (Peer Group 1)
Table 14.18 Product Competitiveness Analysis: Distribution of Spatial Omics Solutions Offered by Mid-sized Companies (Peer Group 2)
Table 14.19 Product Competitiveness Analysis: Distribution of Spatial Omics Solutions Offered by Large Companies (Peer Group 3)
Table 14.20 10x Genomics: Annual Revenues, FY 2017-2021 (USD Billion)
Table 14.21 Akoya Biosciences: Annual Revenues, FY 2019-2021 (USD Million)
Table 14.22 Bruker: Annual Revenues, FY 2017-2021 (USD Million)
Table 14.23 NanoString Technologies: Annual Revenues, FY 2017-2021 (USD Billion)
Table 14.24 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 14.27 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.28 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.29 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.30 Most Active Players: Distribution by Number of Partnerships
Table 14.31 Partnerships and Collaborations: Regional Distribution
Table 14.32 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.33 Patent Analysis: Distribution by Type of Patent
Table 14.34 Patent Analysis: Distribution by Patent Application Year
Table 14.35 Patent Analysis: Distribution by Publication Year
Table 14.36 Patent Analysis: Distribution by Granted Patents
Table 14.37 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications
Table 14.38 Patent Analysis: Distribution by Number of Granted Patents and Patent Applications
Table 14.39 Patent Analysis: Distribution by Geography
Table 14.40 Patent Analysis: Distribution by Patent Age
Table 14.41 Patent Analysis: Distribution by Type of Applicant
Table 14.42 Patent Analysis: Distribution by CPC Symbols
Table 14.43 Leading Players: Distribution by Number of Patents
Table 14.44 Top Inventors: Distribution by Number of Patents
Table 14.45 Patent Analysis: Patent Benchmarking Analysis
Table 14.46 Patent Analysis: Distribution by Patent Valuation Analysis
Table 14.47 Publication Analysis: Distribution by Quarterly trend of publications
Table 14.48 Publication Analysis: Distribution by Type of Publication
Table 14.49 Popular Journals: Distribution by Number of Patents
Table 14.50 Popular Publishers: Distribution by Number of Patents
Table 14.51 Popular Copyright Holders: Distribution by Number of Patents
Table 14.52 Popular Keywords: Distribution by Number of Patents
Table 14.53 Live Cell Instrument Providers: Distribution by Year of Establishment
Table 14.54 Live Cell Instrument Providers: Distribution by Company Size
Table 14.55 Live Cell Instrument Providers: Distribution by Location of Headquarters
Table 14.56 Live Cell Instrument Providers: Distribution by Company Ownership
Table 14.57 Live Cell Instruments: Distribution by Commercial Availability
Table 14.58 Live Cell Instruments: Distribution by Microscope Configuration
Table 14.59 Live Cell Instruments: Distribution by Instrument Weight
Table 14.60 Live Cell Instruments: Distribution by Availability of Integrated Incubator
Table 14.61 Live Cell Instruments: Distribution by Environmental Parameters Controlled
Table 14.62 Live Cell Instruments: Distribution by Availability of Multi-user Mode
Table 14.63 Live Cell Instruments: Distribution by Supported Labware / Cell Culture Vessel
Table 14.64 Live Cell Instruments: Distribution by Z-stack Imaging Capability
Table 14.65 Live Cell Instruments: Distribution by Availability of Autofocus / Semi-Autofocus Mode
Table 14.66 Live Cell Instruments: Distribution by Mode of Imaging
Table 14.67 Live Cell Instruments: Distribution by Number of Fluorescence Channels
Table 14.68 Live Cell Instruments: Distribution by Range of Objectives Available
Table 14.69 World Map Representation: Distribution by Geography
Table 14.70 Global Spatial Omics Solutions Market, 2022-2035 (USD Million)
Table 14.71 Global Spatial Omics Solutions Market: Distribution by Company Size, 2021 and 2030: Base Scenario (USD Million)
Table 14.72 Spatial Omics Solutions Market for Small Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.73 Spatial Omics Solutions Market for Mid-sized Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.74 Spatial Omics Solutions Market for Large Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.75 Global Spatial Omics Solutions Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 14.76 Global Spatial Omics Solutions Market: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Table 14.77 Global Spatial Omics Solutions Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 14.78 Global Spatial Omics Solutions Market: Distribution by End Users, 2022-2035 (USD Million)
Table 14.79 Global Spatial Omics Solutions Market: Distribution by Region, 2022-2035 (USD Million)
Table 14.80 Spatial Omics Solutions Market in North America, 2022-2035 (USD Million)
Table 14.81 Spatial Omics Solutions Market in North America: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 14.82 Spatial Omics Solutions Market in North America: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Table 14.83 Spatial Omics Solutions Market in North America: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 14.84 Spatial Omics Solutions Market in North America: Distribution by End Users, 2022-2035 (USD Million)
Table 14.85 Spatial Omics Solutions Market in Europe, 2022-2035 (USD Million)
Table 14.86 Spatial Omics Solutions Market in Europe: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 14.87 Spatial Omics Solutions Market in Europe: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Table 14.88 Spatial Omics Solutions Market in Europe: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 14.89 Spatial Omics Solutions Market in Europe: Distribution by End Users, 2022-2035 (USD Million)
Table 14.90 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 14.91 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 14.92 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Type of Sample Analyzed, 2022-2035 (USD Million)
Table 14.93 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 14.94 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World: Distribution by End Users, 2022-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 10x Genomics
  2. Abcam
  3. Acuity Spatial Genomics
  4. Advanced Cell Diagnostics
  5. Advanced Genomics 
  6. Aignostics
  7. Akoya Biosciences
  8. Andor Technology
  9. Applied Cells
  10. Arizona State University
  11. AstraZeneca
  12. AtlasXomics
  13. Avacta
  14. Azenta Life Sciences
  15. Bertin Instruments
  16. BestScope
  17. Bethyl Laboratories
  18. BioChain
  19. Bio-Rad Laboratories
  20. BioSense Solutions
  21. BioSpyder Technologies
  22. Bio-Techne
  23. BioTek (acquired by Agilent Technologies) 
  24. Blue-Ray Biotech
  25. Broad Institute of MIT and Harvard
  26. Bruker
  27. California Institute of Technology
  28. Canopy Biosciences (acquired by Bruker)
  29. Carl Zeiss (part of ZEISS)
  30. Cartana (acquired by 10x Genomics)
  31. CD Genomics
  32. CellCarta
  33. Chinese Academy of Sciences
  34. Cold Spring Harbor Laboratory
  35. Columbia University
  36. Columbia University 
  37. CORE Diagnostics (acquired by Canopy Biosciences)
  38. Covance
  39. CrestOptics
  40. CSIR-National Physical Laboratory
  41. Curiosis
  42. Cytena (acquired by CELLINK)
  43. Cytiva
  44. CytoSMART Technologies (acquired by Axion BioSystems) 
  45. Danaher 
  46. De Novo Software
  47. D-Mark Biosciences
  48. Doloromics
  49. EEL Transcriptomics (acquired by Rebus Biosystems)
  50. Element Biosciences
  51. Epredia
  52. Etaluma
  53. European Mass Cytometry Consortium
  54. European Molecular Biology Laboratory
  55. Fluidigm
  56. Fred Hutchinson Cancer Research Center
  57. Harvard Medical School 
  58. Harvard University
  59. HTG Molecular Diagnostics
  60. Hubrecht Institute
  61. Illumina Accelerator
  62. ImaBiotech
  63. Indica Labs
  64. Indivumed
  65. InnoME
  66. Institute for Systems Biology (ISB)
  67. Interpace Biosciences
  68. Ionpath
  69. IPRASENSE
  70. IVIM Technology
  71. Karolinska Institute
  72. Keen Eye
  73. Korea Advanced Institute of Science and Technology
  74. Kyoto University-
  75. L & C BIO
  76. LASE Innovation
  77. Leica Biosystems
  78. Leica Microsystems
  79. Leland Stanford Junior University
  80. LifeOS Genomics
  81. LightSpeed Genomics
  82. Live Cell Instrument (LCI)
  83. Logos Biosystems
  84. Lunaphore Technologies
  85. Massachusetts General Hospital
  86. Massachusetts Institute of Technology
  87. Mayo Clinic Laboratories 
  88. Medical University of South Carolina
  89. Menarini 
  90. Merck
  91. Miltenyi Biotec
  92. Mission Bio 
  93. Molecular Devices
  94. Molecular Machines & Industries (MMI)
  95. MUSC Foundation for Research Development 
  96. NanoEntek 
  97. Nanolive
  98. NanoString Technologies
  99. Nanosys
  100. National Institute for Health and Medical Research (INSERM)
  101. NeoGenomics Laboratories
  102. Nikon
  103. Northwestern University
  104. Novartis
  105. Novogene
  106. Nucleai
  107. Olympus
  108. Oncode Institute
  109. OneD Material
  110. OracleBio
  111. Oregon Health & Science University
  112. Oxford Instruments
  113. Pacific Biosciences
  114. Paige
  115. Panomics
  116. Parker Institute for Cancer Immunotherapy 
  117. Parse Biosciences
  118. PathAI
  119. PercayAI
  120. Perelman School of Medicine, University of Pennsylvania
  121. PerkinElmer
  122. Pharmigene
  123. Phase Holographic Imaging
  124. Phasefocus
  125. Photon 
  126. Pionyr Immunotherapeutics
  127. Precision for Medicine
  128. Princeton University
  129. Prolab Instruments (acquired by Bruker)
  130. Propath UK
  131. Proteona (acquired by Singleron)
  132. Q2 Solutions
  133. Ramot
  134. RareCyte
  135. ReadCoor (acquired by 10x Genomics)
  136. Rebus Biosystems
  137. Resolve Biosciences
  138. Riken Genesis
  139. RIKEN, Center for Integrative Medical Sciences
  140. Roche
  141. Rosalind
  142. S2 Genomics
  143. Sartorius 
  144. SciLifeLab
  145. Scrum
  146. Seven Bridges Genomics
  147. Singular Genomics Systems 
  148. Sirona Dx 
  149. Spatial Genomics
  150. Spatial Transcriptomics (aquired by 10x Genomics)
  151. Stanford University
  152. Takara Bio
  153. Tetramer Shop (acquired by 10x Genomics)
  154. The Johns Hopkins University School of Medicine
  155. The Regents of the University of California
  156. The Rockefeller University
  157. The University of Chicago
  158. The University of Freiburg
  159. The University of Maryland
  160. The University of Münster
  161. The University of Paris
  162. The University of Pennsylvania
  163. The University of Southern California
  164. The University of Texas at Austin
  165. The University of Texas System
  166. Thermo Fisher Scientific
  167. TheryCell
  168. Thistle Scientific
  169. Thunderbio Science
  170. Tomocube
  171. TrendBio
  172. TriBiotica
  173. UCSF Helen Diller Family Comprehensive Cancer Center
  174. Ultivue
  175. Unitag Bio
  176. Universal Sequencing Technology
  177. University of Bern
  178. University of California
  179. University of Pittsburgh
  180. University of Washington
  181. Veranome Biosystems
  182. Verily Life Sciences
  183. VIB
  184. Visiopharm
  185. Vitro
  186. Vizgen
  187. Vyant Bio
  188. Wave Life Sciences
  189. Weizmann Institute of Science
  190. Wyss Institute
  191. XGenomes
  192. Yale University
  193. Zellkraftwerk (acquired by Canopy Biosciences)
  194. Zhejiang PuLuoTing Health Technology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com